{
  "id": "afib",
  "name": "Atrial Fibrillation / Flutter",
  "category": ["Arrhythmia"],
  "clinical_triggers": {
    "symptoms_any": [
      "Palpitations",
      "Dyspnea",
      "Fatigue",
      "Chest discomfort",
      "Dizziness/syncope"
    ],
    "signs_any": ["Irregularly irregular pulse", "Tachycardia", "Variable BP"]
  },
  "initial_tests": [
    "12‑lead ECG (irregularly irregular rhythm, absent P waves)",
    "TSH, BMP/Mg, CBC; consider troponin if ischemia suspected",
    "Echocardiogram (structure, LA size, valves, LV function)"
  ],
  "risk_scoring": {
    "anticoagulation": "Use CHA₂DS₂‑VASc to guide anticoagulation",
    "bleeding_risk": "HAS‑BLED for bleeding risk (do not use to withhold OAC outright)"
  },
  "treatment": {
    "acute": [
      "Unstable (hypotension/ischemia/HF): immediate synchronized cardioversion",
      "Stable: rate control (β‑blocker or diltiazem/verapamil); consider digoxin if hypotension/HFrEF",
      "Anticoagulation strategy based on CHA₂DS₂‑VASc and duration of AF"
    ],
    "rhythm_control": [
      "Electrical cardioversion if appropriate (consider TEE to exclude LAA thrombus if >48h or unknown)",
      "Antiarrhythmics in selected patients (amiodarone, dofetilide, flecainide/propafenone if no structural heart disease)",
      "Catheter ablation for symptomatic AF refractory or intolerant to AADs"
    ],
    "rate_control": [
      "β‑blocker or non‑DHP CCB (verapamil/diltiazem) for most patients",
      "Add digoxin in HFrEF or low BP limiting other agents"
    ],
    "anticoagulation": [
      "DOAC preferred over warfarin in eligible patients",
      "Peri‑cardioversion anticoagulation per guideline (≥3 weeks before and 4 weeks after if >48h or unknown duration)"
    ]
  },
  "contraindications": {
    "non_dhp_ccb": ["Avoid in HFrEF with decompensation"],
    "class_ic": ["Avoid in structural heart disease or CAD (proarrhythmia)"]
  },
  "discharge": {
    "instructions": [
      "Stroke prevention plan documented (OAC if indicated)",
      "Education on rate/rhythm meds and when to seek care (worsening palpitations, syncope, chest pain)"
    ],
    "follow_up": [
      "Cardiology EP follow‑up; consider sleep apnea evaluation and risk factor modification (weight loss, ETOH moderation)"
    ]
  }
}
